BMY — Recent News Coverage

BNTX and BMY announced Phase 2 data for pumitamig, a candidate targeting advanced non-small cell lung cancer (NSCLC) in a post-immunotherapy setting. The trial demonstrated a 36.7% objective response rate and 6.9-month …

AstraZeneca (AZN) experienced a significant 9% single-day decline on merger speculation involving Bristol-Myers Squibb (BMY), marking the largest drop since 2020. Market skepticism around the potential combination signa…

The article reflects a thematic rotation narrative where portfolio managers seek innovation exposure outside the technology sector after an extended tech rally. Large-cap pharmaceutical companies—particularly JNJ, LLY, …

Schrödinger (SDGR) reported robust Q2 2026 results with 27% annual contract value (ACV) growth, materially outpacing its forward guidance of 10%-15% for full-year 2026. This outperformance signals accelerating adoption …

Disney is displaying meaningful operational momentum across multiple revenue streams, with theatrical blockbuster performance and theme park strength providing dual tailwinds to earnings capacity. The asset mix suggests…

Bristol-Myers Squibb (BMY) faced downward pressure following reports that no active merger or acquisition discussions are underway with AstraZeneca (AZN). The denial of ongoing talks suggests market speculation about a …

Analyst commentary on a potential acquisition of Bristol-Myers Squibb (BMY) by AstraZeneca (AZN) suggests such a transaction remains unlikely in the near term. This represents a reassessment of earlier market speculatio…

AstraZeneca has outperformed peer benchmarks in pharma growth metrics, signaling stronger pipeline execution and commercial momentum relative to competitors. This reflects operational discipline and successful market po…

Alibaba announced Qwen3.8-Max, advancing its competitive position in the large language model race. This launch represents continued investment in generative AI infrastructure and signals intensifying competition agains…

Bristol-Myers Squibb (BMY) has reached a 52-week high following robust second-quarter earnings results and management's upward revision of earnings-per-share guidance. The stock's strength reflects confidence in the com…

NVDA and the broader semiconductor complex are showing strength as institutional adoption of AI-capable chips accelerates. Bristol Myers Squibb's capital deployment toward Nvidia hardware for drug discovery validates th…

Bristol Myers Squibb's elevated dividend yield of 4.3% reflects both investor appetite for pharma income and underlying concerns about the company's valuation and growth trajectory. The yield sits above both sector and …

Bristol Myers Squibb (BMY) has been flagged as undervalued within the pharmaceutical sector, with analyst commentary emphasizing a disconnect between current valuation and fundamental earnings power. The thesis centers …

Bristol-Myers Squibb (BMY) faces potential headwinds from proposed updates to the Medicare Drug Price Negotiation Program, a regulatory mechanism introduced under the Inflation Reduction Act. The proposed changes repres…

Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ) represent divergent strategies within large-cap healthcare. BMY's positioning in specialty medicines creates concentrated exposure to high-margin therapeutic areas,…

Bristol Myers Squibb (BMY) is the focal point of this dividend safety assessment, with the company offering a 4.5% yield that significantly exceeds broad market averages. This above-market income profile attracts yield-…

Bristol Myers Squibb (BMY) continues to demonstrate capital allocation discipline through an 18-year consecutive dividend increase streak, a notable achievement in the pharmaceutical sector where cash generation and sha…